語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
mTOR inhibition for cancer therapy =...
~
Mita, Monica.
FindBook
Google Book
Amazon
博客來
mTOR inhibition for cancer therapy = past, present and future /
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
mTOR inhibition for cancer therapy/ edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
其他題名:
past, present and future /
其他作者:
Mita, Monica.
出版者:
Paris :Springer Paris : : 2016.,
面頁冊數:
vi, 300 p. :ill. (some col.), digital ;24 cm.
內容註:
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
Contained By:
Springer eBooks
標題:
Cancer - Treatment. -
電子資源:
http://dx.doi.org/10.1007/978-2-8178-0492-7
ISBN:
9782817804927$q(electronic bk.)
mTOR inhibition for cancer therapy = past, present and future /
mTOR inhibition for cancer therapy
past, present and future /[electronic resource] :edited by Monica Mita, Alain Mita, Eric K. Rowinsky. - Paris :Springer Paris :2016. - vi, 300 p. :ill. (some col.), digital ;24 cm.
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
ISBN: 9782817804927$q(electronic bk.)
Standard No.: 10.1007/978-2-8178-0492-7doiSubjects--Topical Terms:
618125
Cancer
--Treatment.
LC Class. No.: RC270.8
Dewey Class. No.: 616.994
mTOR inhibition for cancer therapy = past, present and future /
LDR
:02908nmm a2200313 a 4500
001
2029299
003
DE-He213
005
20160726141129.0
006
m d
007
cr nn 008maaau
008
160908s2016 fr s 0 eng d
020
$a
9782817804927$q(electronic bk.)
020
$a
9782817804910$q(paper)
024
7
$a
10.1007/978-2-8178-0492-7
$2
doi
035
$a
978-2-8178-0492-7
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC270.8
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
082
0 4
$a
616.994
$2
23
090
$a
RC270.8
$b
.M939 2016
245
0 0
$a
mTOR inhibition for cancer therapy
$h
[electronic resource] :
$b
past, present and future /
$c
edited by Monica Mita, Alain Mita, Eric K. Rowinsky.
260
$a
Paris :
$b
Springer Paris :
$b
Imprint: Springer,
$c
2016.
300
$a
vi, 300 p. :
$b
ill. (some col.), digital ;
$c
24 cm.
505
0
$a
Forward -- Past -- mTOR inhibitors: a little bit of history -- Present -- The mTOR pathway -- The evolving role of mTOR inhibitors in renal cell carcinoma -- The role of mTOR inhibitors in breast cancer -- The role of mTOR inhibitors in neuroendocrine tumors -- New indications of mTOR inhibitors in rare tumors -- The role of mTOR inhibitors in the treatment of hematological malignancies -- The clinical pharmacology and toxicity profile of rapalogs -- Resistance to mTOR inhibitors -- Rational combinations of mTOR inhibitors as anticancer strategies -- Future -- Predictive biomarkers of response to mTOR inhibitors -- The potential future indication of rapamycin analogs for the treatment of other solid tumors -- mTOR inhibition beyond rapalogs -- mTOR, aging and cancer: the missing link? -- New study design for mTOR inhibitors and other biological agents -- Future directions for the development of mTOR inhibitors.
520
$a
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
650
0
$a
Cancer
$x
Treatment.
$3
618125
650
0
$a
Medicine.
$3
641104
650
0
$a
Molecular biology.
$3
517296
650
0
$a
Hematology.
$3
808260
650
0
$a
Oncology.
$3
751006
650
1 4
$a
Medicine & Public Health.
$3
890906
650
2 4
$a
Molecular Medicine.
$3
890952
700
1
$a
Mita, Monica.
$3
2180193
700
1
$a
Mita, Alain.
$3
2180194
700
1
$a
Rowinsky, Eric K.
$3
2180195
710
2
$a
SpringerLink (Online service)
$3
836513
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-2-8178-0492-7
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9276563
電子資源
11.線上閱覽_V
電子書
EB RC270.8 .M939 2016
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入